AG
GNMK

Aperio Group’s GenMark Diagnostics, Inc GNMK Stock Holding History

Aperio Group’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$268K Buy
+18,327
New +$243K ﹤0.01% 2224
2020
Q2 		– Sell
-10,174
Closed -$42K – 2416
2020
Q1 		$42K Buy
+10,174
New +$47.7K ﹤0.01% 2282
2019
Q3 		– Sell
-2,705
Closed -$18K – 2936
2019
Q2 		$18K Buy
+2,705
New +$19.1K ﹤0.01% 2707

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aperio Group's GNMK Position: Q4 2020 in Review

Aperio Group opened a new position in GenMark Diagnostics, Inc (GNMK) in Q4 2020: 18,327 shares worth $268K. The stake represents ﹤0.01% of the portfolio and ranks #2224 among its holdings. This is a return to the name: Aperio Group previously reported a position in GNMK as recently as Q1 2020.

Aperio Group first reported a position in GNMK in Q2 2019 and has held it in 3 quarters since. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • Aperio Group held 18,327 shares of GenMark Diagnostics, Inc worth $268K as of Q4 2020.
  • GenMark Diagnostics, Inc was a new Aperio Group position in Q4 2020.
  • GenMark Diagnostics, Inc made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2224 holding.
  • Aperio Group first reported a position in GenMark Diagnostics, Inc in Q2 2019 and has held it in 3 quarters since.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.